Stay updated on Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov page’s footer revision identifier changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe clinical trial record is now available with its study design, eligibility criteria, outcomes, and associated documents. It reports that the Phase II trial of nivolumab plus ipilimumab was terminated after the first 10 patients because it met prespecified futility criteria.SummaryDifference55%

- Check21 days agoChange DetectedThe 403 Forbidden message and its Home link disappear, leaving the ClinicalTrials.gov page shell without visible study details. The site revision changes from v3.7.2 to v3.8.0.SummaryDifference0.6%

- Check28 days agoChange DetectedA banner announces NIH website transition updates and says both “Super Intelligence” and “Artificial Intelligence” terminology may appear during the transition.SummaryDifference1%

- Check35 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2 while the page continues to show a 403 error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe footer revision number changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.